A COMPARATIVE STUDY ON SAFETY, EFFICACY AND PHARMACOTHERAPEUTIC ADHERENCE OF DESVENLAFAXINE VERSUS ESCITALOPRAM IN DEPRESSION AT A TERTIARY CARE TEACHING HOSPITAL
Main Article Content
Keywords
Major Depressive Disorder, Escitalopram, Desvenlafaxine, HAM-D, SSRI, SNRI
Abstract
INTRODUCTION
Major Depressive Disorder (MDD) is a prevalent mental health condition, with pharmacological treatments like Escitalopram (SSRI) and Desvenlafaxine (SNRI) being widely used. This study compared their efficacy, safety, adherence and metabolic effects in MDD patients.
OBJECTIVES
The primary objective was to evaluate depressive symptom reduction using the Hamilton Depression Rating Scale (HAM-D) over 16 weeks. Secondary objectives included assessing lipid profiles, platelet counts, adverse effects and adherence.
METHODS
This prospective observational study included 203 MDD patients (Escitalopram: n=105; Desvenlafaxine: n=98). HAM-D scores, lipid profiles, and platelet counts were evaluated at baseline and week 16. Adverse effects were monitored throughout the study.
RESULTS
Both treatments significantly reduced HAM-D scores (p < 0.001), with Escitalopram showing greater improvement at all time points (p < 0.001). Escitalopram improved lipid profiles, reducing TC (p < 0.001), TG (p < 0.001), and VLDL (p < 0.001), while increasing HDL (p < 0.001). LDL remained unchanged (p = 0.842). Desvenlafaxine increased TC (p < 0.001) and VLDL (p < 0.001) but also raised HDL (p < 0.001), with no significant changes in TG (p = 0.954) or LDL (p = 0.839). Platelet counts decreased slightly with Escitalopram (p = 0.012) but remained stable with Desvenlafaxine (p = 0.806). Adverse effects were more frequent with Desvenlafaxine (9.2% at 4 weeks) than Escitalopram (6.7%).
CONCLUSION
Escitalopram demonstrated superior efficacy in reducing depressive symptoms and a more favourable impact on lipid profiles compared to Desvenlafaxine, which had a higher incidence of adverse effects. Escitalopram is preferable for MDD patients with metabolic concerns, while Desvenlafaxine remains a viable alternative with careful monitoring. Individualized treatment strategies are essential for optimal MDD management.
References
2. World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization; 2017.
3. Radden J. The nature of melancholy: from Aristotle to Kristeva. New York: Oxford University Press; 2009.
4. Shorter E. A history of psychiatry: from the era of the asylum to the age of Prozac. New York: Wiley; 1997.
5. Valenstein ES. Great and desperate cures: the rise and decline of psychosurgery and other radical treatments for mental illness. New York: Basic Books; 1986.
6. Healy D. The antidepressant era. Cambridge (MA): Harvard University Press; 1997.
7. Wong DT, Bymaster FP. The discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov. 2002;1(7):539-44.
8. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-66.
9. Montgomery SA, Baldwin DS. Escitalopram: a review of its use in the management of major depressive disorder. Drugs. 2006;66(13):1759-71.
10. Lieberman DZ, Montgomery SA, Tourian KA. Desvenlafaxine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2008;4(2):465-74.
11. Central Drugs Standard Control Organisation. Approval for desvenlafaxine. New Delhi: Central Drugs Standard Control Organisation; 2009.
12. Demyttenaere K, Van Ganse E. Compliance and adherence in the treatment of depression. CNS Drugs. 2009;23(3):229-39.
13. Patel V, Kleinman A. Poverty and common mental disorders in developing countries. Bull World Health Organ. 2003;81(8):609-15.
14. Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. 4th ed. Cambridge: Cambridge University Press; 2013.
15. Trivedi MH, Daly EJ. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend. 2007;88 Suppl 2:S61-71.
16. Maity N, Sen S, Chatterjee SS, Saha A, Das AK, Dasgupta A. Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial. Indian J Pharmacol. 2014;46(4):433-7. doi: 10.4103/0253-7613.135959.
17. Lee SH, Lee YJ, Kim SH, Han KM, Ham BJ. Acute efficacy and safety of escitalopram versus desvenlafaxine and vortioxetine in the treatment of depression with cognitive complaint: a rater-blinded randomized comparative study. Psychiatry Investig. 2022;19(4):268-80. doi: 10.30773/pi.2021.0368.
18. Gupta BM, Lal B, Singh H, Tiwari R, Prakash J, Chauhan M. Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: a preliminary 1-year prospective randomized open-label comparative trial. Perspect Clin Res. 2016;7(1):45-50. doi: 10.4103/2229-3485.173771.
19. Bandaru S, Alivelu A, Bai KS, Yendluri P. Safety and efficacy of desvenlafaxine with escitalopram among the patients of depression associated with anxiety: a randomized, open-labeled, comparative study. Natl J Physiol Pharm Pharmacol. 2024;14(1):74-80. doi: 10.5455/njppp.2023.13.05223202301062023.
20. Ashique A A, Abdul R M, Humayion K, Barkat A M. Reduction of Serum Lipid Profile by Escitalopram in Depressive Patients: A Cardio Protective Aspect of SSRI Use. J Cardiol & Cardiovasc Ther 2017; 4(4): 555642. DOI: 10.19080/JOCCT.2017.04.555642..
21. Unis A, Abdelbary A, Hamza M. Comparison of the effects of escitalopram and atorvastatin on diet-induced atherosclerosis in rats. Can J Physiol Pharmacol. 2014;92(3):231-7.
22. Tourian KA, Padich R, Groark J, Auby P, Mandos LA, Schweizer E. A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder. Prim Care Companion CNS Disord. 2011;13(2):PCC.10m00977. doi: 10.4088/PCC.10m00977blu.
23. Song H, Jung YE, Wang HR, Woo YS, Jun TY, Bahk WM. Platelet count alterations associated with escitalopram, venlafaxine, and bupropion in depressive patients: platelet count and antidepressants. Psychiatry Clin Neurosci. 2012;66(6):457-9. doi: 10.1111/j.1440-1819.2012.02355.x.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. BK Shoraisham
GSVM Medical College, Kanpur
Dr. Virendra Kushwaha
GSVM Medical College, Kanpur
Dr. Pooja Agrawal
GSVM Medical College, Kanpur
Dr. Dhananjay Chaudhari
GSVM Medical College, Kanpur
Dr. Amit Kumar
Rajkiya Medical College, Jalaun
Dr. Himanshu Sharma
GSVM Medical College, Kanpur